68Ga-DOTATATE Uptake in Primary Breast Cancer

Research output: Contribution to journalArticlepeer-review


68Ga-DOTA peptides have revolutionized the imaging of neuroendocrine tumors because the agents are specific to somatostatin receptors. However, other tumors, including breast cancer, have been shown to express somatostatin receptors. We present the case of a 74-year-old woman with primary cardiac paraganglioma, who was found to have 68Ga-DOTATATE activity in the breast on staging PET/CT. Subsequent breast imaging workup and biopsy confirmed primary invasive lobular breast cancer, which was not 18F-FDG-avid on prior FDG PET/CT. Our case is in alignment with prior studies that suggest that 68Ga-DOTA peptides may play a future role in imaging breast cancer patients.

Original languageEnglish (US)
Pages (from-to)248-249
Number of pages2
JournalClinical nuclear medicine
Issue number3
StatePublished - 2021


  • PET
  • breast cancer
  • invasive lobular carcinoma
  • somatostatin receptor radioligands

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of '<sup>68</sup>Ga-DOTATATE Uptake in Primary Breast Cancer'. Together they form a unique fingerprint.

Cite this